fficacy and Safety of Bosutinib Vs Imatinib By Charlson Comorbidity Index in Newly Diagnosed Patients with Chronic Myeloid Leukemia

被引：0
|
作者：
Deininger, Michael W. [1 ]
Brummendorf, Tim H. [2 ,3 ]
Lipton, Jeffrey H. [4 ]
Milojkovic, Dragana [5 ]
Stenke, Leif [6 ,7 ]
Leip, Eric [9 ]
Purcell, Simon [8 ,10 ]
Viqueira, Andrea [11 ]
Cortes, Jorge E. [12 ]
机构：
[1] Univ Utah, Huntsman Canc Inst, Div Hematol & Hematol Malignancies, Salt Lake City, UT USA
[2] Univ Med Ctr Aachen, Dept Internal Med 4, Aachen, Germany
[3] Univ Klinikum RWTH Aachen, Med Klin 4, Aachen, Germany
[4] Princess Margaret Canc Ctr, Hans Messner Allogene Blood & Marrow Transplant U, Toronto, ON, Canada
[5] Imperial Coll NHS Trust, Hammersmith Hosp, Dept Haematol, London, England
[6] Karolinska Univ Hosp, Dept Hematol, Theme Canc, Stockholm, Sweden
[7] Karolinska Univ Hosp, Dept Med Solna, Stockholm, Sweden
[8] Karolinska Inst, Stockholm, Sweden
[9] Pfizer Inc, Cambridge, MA USA
[10] Pfizer Ltd, London, England
[11] Pfizer SLU, Madrid, Spain
[12] Augusta Univ, Georgia Canc Ctr, Augusta, GA USA
来源：
BLOOD | 2022年 / 140卷
关键词：
D O I：
10.1182/blood-2022-163276
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：3913 / 3915
页数：3
相关论文
共 50 条
  • [21] Outcomes before and after dose reduction in patients with newly diagnosed chronic myeloid leukemia receiving bosutinib or imatinib.
    Deininger, Michael W.
    Brummendorf, Tim H.
    Milojkovic, Dragana
    Cervantes, Francisco
    Huguet, Francoise
    Viqueira, Andrea
    Leip, Eric
    Purcell, Simon
    Cortes, Jorge E.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [22] Efficacy and safety of bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia in the Asian subpopulation of the phase 3 BFORE trial
    Charles Chuah
    Liang Piu Koh
    Tontanai Numbenjapon
    Dae Young Zang
    Kiat Hoe Ong
    Young Rok Do
    Masayuki Ohkura
    Chiho Ono
    Andrea Viqueira
    Jorge E. Cortes
    Tim H. Brümmendorf
    International Journal of Hematology, 2021, 114 : 65 - 78
  • [23] Efficacy and safety of bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia in the Asian subpopulation of the phase 3 BFORE trial
    Chuah, Charles
    Koh, Liang Piu
    Numbenjapon, Tontanai
    Zang, Dae Young
    Ong, Kiat Hoe
    Do, Young Rok
    Ohkura, Masayuki
    Ono, Chiho
    Viqueira, Andrea
    Cortes, Jorge E.
    Brummendorf, Tim H.
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2021, 114 (01) : 65 - 78
  • [24] Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial
    Cortes, Jorge E.
    Gambacorti-Passerini, Carlo
    Deininger, Michael W.
    Mauro, Michael J.
    Chuah, Charles
    Kim, Dong-Wook
    Dyagil, Irina
    Glushko, Nataliia
    Milojkovic, Dragana
    le Coutre, Philipp
    Garcia-Gutierrez, Valentin
    Reilly, Laurence
    Jeynes-Ellis, Allison
    Leip, Eric
    Bardy-Bouxin, Nathalie
    Hochhaus, Andreas
    Brummendorf, Tim H.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (03) : 231 - +
  • [25] Imatinib in patients with newly diagnosed chronic-phase chronic myeloid leukemia
    O'Brien, SG
    Deininger, MWN
    SEMINARS IN HEMATOLOGY, 2003, 40 (02) : 26 - 30
  • [26] IMATINIB MESYLATE IN NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA (CML) PATIENTS
    Ionita, H.
    Ionita, I.
    Cheveresan, M.
    Iordache, M.
    Cheveresan, L.
    Ionita, M.
    Borzak, G.
    Ionita, C. O.
    Pascalau, A.
    Calamar, D.
    Oros, D.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 548 - 548
  • [27] Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial
    Brummendorf, Tim H.
    Cortes, Jorge E.
    Milojkovic, Dragana
    Gambacorti-Passerini, Carlo
    Clark, Richard E.
    le Coutre, Philipp
    Garcia-Gutierrez, Valentin
    Chuah, Charles
    Kota, Vamsi
    Lipton, Jeffrey H.
    Rousselot, Philippe
    Mauro, Michael J.
    Hochhaus, Andreas
    Hurtado Monroy, Rafael
    Leip, Eric
    Purcell, Simon
    Yver, Anne
    Viqueira, Andrea
    Deininger, Michael W.
    LEUKEMIA, 2022, 36 (07) : 1825 - 1833
  • [28] Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial
    Tim H. Brümmendorf
    Jorge E. Cortes
    Dragana Milojkovic
    Carlo Gambacorti-Passerini
    Richard E. Clark
    Philipp le Coutre
    Valentin Garcia-Gutierrez
    Charles Chuah
    Vamsi Kota
    Jeffrey H. Lipton
    Philippe Rousselot
    Michael J. Mauro
    Andreas Hochhaus
    Rafael Hurtado Monroy
    Eric Leip
    Simon Purcell
    Anne Yver
    Andrea Viqueira
    Michael W. Deininger
    Leukemia, 2022, 36 : 1825 - 1833
  • [29] Bosutinib Versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Results From the BELA Trial
    Cortes, Jorge E.
    Kim, Dong-Wook
    Kantarjian, Hagop M.
    Bruemmendorf, Tim H.
    Dyagil, Irina
    Griskevicius, Laimonas
    Malhotra, Hemant
    Powell, Christine
    Gogat, Karin
    Countouriotis, Athena M.
    Gambacorti-Passerini, Carlo
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (28) : 3486 - 3492
  • [30] Preliminary comparison of efficacy and safety of dasatinib and imatinib in newly diagnosed chronic myeloid leukemia
    周励
    ChinaMedicalAbstracts(InternalMedicine), 2013, 30 (02) : 123 - 123
12345